How Long Has Ivermectin Been Around? A 50-Year History from 1974 to the Present

✨ This article was AI edited. Editorial responsibility: Ivermectinfordogs.org.

Overview: Five Decades of Antiparasitic Pharmacology

Few pharmaceuticals in modern medicine possess a clinical track record as extensive, diverse, and heavily documented as ivermectin. From its initial microbiological isolation in 1974 to its current status on the World Health Organization’s (WHO) Model List of Essential Medicines, ivermectin has accumulated over five decades of scientific investigation and commercial deployment.

Understanding exactly how long ivermectin has been in clinical use requires distinguishing between its multiple regulatory milestones: laboratory discovery, veterinary commercialization, human oral approvals, and modern topical dermatological formulations. Across all sectors, billions of doses have been administered to livestock, companion animals, and humans worldwide, establishing one of the most comprehensive pharmacokinetic and safety datasets in pharmacology.

The Four Eras of Ivermectin’s Fifty-Year History

1974–1980: The Discovery and Chemical Innovation Phase

The history of ivermectin commenced in 1974 when Dr. Satoshi Ōmura of Tokyo’s Kitasato Institute collected an actinomycete bacterium from a soil sample near Kawana, Ito City, Japan. Transferred to Merck Research Laboratories in New Jersey under a joint international research accord, the bacterial culture was shown by Dr. William C. Campbell to produce powerful natural anthelmintics dubbed avermectins.

By 1978, Merck medicinal chemists synthesized 22,23-dihydroavermectin B1—a molecular modification that enhanced chemical stability and widened the margin of safety for mammalian hosts. This chemically optimized compound was formally designated “ivermectin.” During this six-year period, rigorous pre-clinical safety trials, pharmacokinetic profiling, and radiolabeled excretion studies laid the empirical foundation for its subsequent approvals.

1981: The Launch of Veterinary Ivermectin (45 Years in Practice)

Ivermectin entered commercial use in 1981, marking its formal debut as an approved pharmaceutical. Introduced under brand names such as Ivomec for livestock and Eqvalan for equines, ivermectin transformed global agricultural parasitology overnight.

Prior to 1981, managing gastrointestinal worms, lungworms, cattle grubs, lice, and mites in commercial livestock required frequent, labor-intensive administration of toxic organophosphates or older benzimidazoles with narrow safety margins. Ivermectin provided broad-spectrum control against both internal nematodes and external ectoparasites (endectocide activity) at microgram-per-kilogram doses, drastically improving livestock welfare and agricultural productivity.

In 1987, Merck introduced Heartgard (ivermectin) for domestic canines. Dosed at a miniscule 6 micrograms per kilogram of body weight once monthly, it eradicated third- and fourth-stage larvae of Dirofilaria immitis (heartworm), establishing the gold standard of companion animal preventive medicine for over thirty-five years.

1987: Human Clinical Approval and the Mectizan Donation Program

While veterinary use began in 1981, human administration of ivermectin officially commenced in October 1987. After extensive clinical trials in Senegal, Ghana, and Mali demonstrated that ivermectin safely cleared Onchocerca volvulus microfilariae from human dermal and ocular tissues, French regulatory authorities approved oral ivermectin under the trade name Mectizan.

Concurrently, Merck’s CEO Dr. P. Roy Vagelos announced the historic Mectizan Donation Program. Recognizing that the impoverished rural populations afflicted with river blindness across West and Central Africa could never afford commercial drug purchases, Merck pledged to supply Mectizan free of charge to all endemic countries for as long as necessary. Since 1987, over 4.5 billion treatments have been distributed in partnership with the World Health Organization (WHO), UNICEF, and the Carter Center.

1996: United States FDA Approval for Human Use (Stromectol)

In the United States, the Food and Drug Administration (FDA) approved oral ivermectin for human use on November 22, 1996, under the brand name Stromectol (manufactured by Merck & Co., Inc.). The FDA granted approval for two specific indications:

• Strongyloidiasis: Intestinal infection caused by the roundworm nematode Strongyloides stercoralis (standard dosage: 200 mcg/kg as a single oral dose or repeated two-dose regimen).
• Onchocerciasis: Extraintestinal parasitic disease caused by Onchocerca volvulus (standard dosage: 150 mcg/kg as a single oral dose taken annually or semi-annually).

Beyond these labeled approvals, board-certified clinicians have utilized Stromectol off-label for decades as the standard systemic treatment for severe crusted (Norwegian) scabies, treatment-resistant Sarcoptes scabiei, and cutaneous larva migrans.

2012–Present: Topical Approvals and the Nobel Prize

Over the past fifteen years, pharmaceutical researchers expanded ivermectin’s therapeutic reach into dermatological medicine through specialized topical formulations:

• February 2012: The US FDA approved Sklice (ivermectin lotion, 0.5%) for the topical treatment of head lice (Pediculus humanus capitis) in patients 6 months of age and older. In 2020, Sklice was approved for over-the-counter (OTC) status.
• December 2014: The US FDA approved Soolantra (ivermectin cream, 1%) for the once-daily topical treatment of inflammatory lesions of rosacea, functioning through both anti-inflammatory properties and eradication of microscopic Demodex folliculorum facial mites.
• December 2015: The Nobel Assembly at Karolinska Institutet awarded the 2015 Nobel Prize in Physiology or Medicine jointly to William C. Campbell and Satoshi Ōmura for their discovery of avermectins, formalizing ivermectin’s legacy as one of the most consequential drug discoveries in history.

Comprehensive Milestones Timeline (1974 – 2026)

Frequently Asked Questions (FAQ)